



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-976/S-003

NDA 21-976/S-004

Tibotec, Inc.
Attention: Jenny Z. Lin, Pharm.D.
Sr. Manager, Global Regulatory Affairs
1020 Stony Hill Road, Suite 300
Yardley, PA 19067

Dear Dr. Lin:

Please refer to your supplemental new drug applications dated March 28, 2007 and August 6, 2007 received March 28, 2007 and August 6, 2007, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prezista™ (darunavir) tablets.

We acknowledge receipt of your submissions dated September 27, 2007, October 29, 2007, February 4, 2008, and March 3, 2008.

The supplement dated March 28, 2007 provides for updates to the CLINICAL PHARMACOLOGY section of the package insert to include data from 6 pharmacokinetic, drug interaction Phase 1 trials.

The “Changes Being Effected” supplemental new drug application dated August 6, 2007 provides for updates to the WARNINGS, PRECAUTIONS AND ADVERSE EVENTS section of the package insert to include hepatotoxicity information and updates to PRECAUTIONS’, Table 11 to include information regarding a potential drug-drug interaction with rosuvastatin.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text enclosed below.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert, text for the patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, “SPL for approved NDA 21-976/S003 and S004.”

In addition, within 21 days of the date of this letter, amend any pending applications for this NDA with content of labeling in structured product labeling (SPL) format to include the changes approved in these applications.

Marketing the product with FPL that is not identical to the approved labeling text and in the required format may render the product misbranded and an unapproved new drug.

The Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the revised product labeling and has determined that it contains significant new risk information relating to your drug product. We are hereby requesting that all promotional materials for your drug product that include representations about your drug product be revised to include the new risk information immediately. These revisions should include prominent disclosure of the important new information described in the WARNINGS and PRECAUTIONS sections that appear in the revised package labeling. Please submit a written response to this request on or before March 14, 2008, stating whether you intend to comply with this request, to the Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications by facsimile at (301)796-9878 or at 5901-B Ammendale Road, Beltsville, MD 20705.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Antiviral Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21-976/S003
NDA 21-976/S004

- 3 -

If you have any questions, please call Tanima Sinha, M.S., Regulatory Project Manager, at (301) 796-0812.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: final agreed upon labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Jeffrey Murray
3/7/2008 01:20:27 PM